---
document_datetime: 2025-12-02 05:05:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dexdor.html
document_name: dexdor.html
version: success
processing_time: 0.1152315
conversion_datetime: 2025-12-24 08:58:32.302509
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dexdor

[RSS](/en/individual-human-medicine.xml/65984)

##### Authorised

This medicine is authorised for use in the European Union

dexmedetomidine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dexdor](#news-on)
- [More information on Dexdor](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dexdoris a medicine used to sedate (calm or make sleepy) adult patients in the following settings:

- in hospital intensive care units to bring about a light level of sedation in which the patient can still respond to verbal stimulation (corresponding to a score of between 0 and -3 on the Richmond Agitation-Sedation Scale);
- before or during diagnostic or surgical procedures where the patient remains awake (awake sedation).

Dexdor contains the active substance dexmedetomidine.

Expand section

Collapse section

## How is Dexdor used?

Dexdor can only be obtained with a prescription and should be given by a healthcare professional skilled in managing patients in intensive care or giving anaesthetic during diagnostic or surgical procedures.

Dexdor is given by infusion (drip) into a vein using a controlled infusion device.

When Dexdor is used in intensive care, the dose is adjusted to achieve the desired level of sedation. If sedation with the maximum dose is not adequate, the patient can be switched to other medicines.

When Dexdor is used for awake sedation in diagnostic or surgical procedures, the starting dose depends on the type of procedure and the dose is adjusted to achieve the desired effect. In some cases, the patient is also given a local anaesthetic, painkillers and other sedative medicines. The patient's blood pressure, heart rate, breathing and oxygen levels should be monitored closely during the procedure.

Care should be taken when using Dexdor in patients with reduced liver function and the dose may be reduced.

For more information about using Dexdor, see the package leaflet or contact your doctor or pharmacist.

## How does Dexdor work?

The active substance in Dexdor, dexmedetomidine, is a selective alpha-2 receptor agonist. It works by blocking receptors in the brain called alpha-2 receptors and reduces the activity of the sympathetic nervous system which is involved in controlling anxiety, arousal and sleep as well as blood pressure and heart rate. By reducing the activity of the sympathetic nervous system, dexmedetomidine helps to make patients calm or sleepy.

## What benefits of Dexdor have been shown in studies?

**Sedation in intensive care**

Dexdor was compared with other sedative medicines (propofol or midazolam) in two main studies involving 1,000 patients who required sedation in intensive care units. The main measures of effectiveness were how well the medicines maintained the required sedation level and the time patients needed to spend on a mechanical ventilator (a machine that 'breathes' for the patient).

In the first study, 65% of patients given Dexdor maintained the required level of sedation compared with 65% of those receiving propofol. In the second study, 61% of patients given Dexdor maintained the required level of sedation compared with 57% of those receiving midazolam. The studies also showed that Dexdor reduced the duration of mechanical ventilation.

**Awake sedation during diagnostic or surgical procedures**

Dexdor was compared with placebo (a dummy treatment) in two main studies involving 431 patients. A higher proportion of patients treated with Dexdor did not require additional treatment with midazolam (another sedative medicine) to maintain the desired sedation level.

The first study involved patients undergoing surgery or a procedure under an anaesthetic block (where sensation to a part of the body is blocked). Patients in the Dexdor group received either 0.5 or 1 microgram/kg bodyweight. Midazolam treatment was not required in 40% of patients receiving the lower dose of Dexdor and 54% of those receiving the higher dose compared with 3% of patients receiving placebo.

The second study involved patients undergoing a fibreoptic intubation (inserting a breathing tube through the nose or the mouth into the windpipe) while patients are awake. Midazolam treatment was not required in 53% of patients receiving Dexdor compared with 14% receiving placebo.

## What are the risks associated with Dexdor?

The most common side effects with Dexdor (which may affect more than 1 in 10 people) when it is used in intensive care are low or high blood pressure and bradycardia (slow heart rate). The most common side effects when it is used for awake sedation are low blood pressure, respiratory depression (reduced ability to breathe) and bradycardia.

Dexdor must not be used in patients with advanced heart block (a type of heart rhythm disorder), patients with uncontrolled low blood pressure and in patients with conditions such as stroke that affect the blood supply to the brain.

For the full list of side effects and restrictions with Dexdor, see the package leaflet.

## Why is Dexdor authorised in the EU?

The studies in intensive care showed that Dexdor compared well with other sedatives. It is effective  for awake sedation during procedures but sometimes an additional sedative medicine as well as Dexdor may be needed. Dexdor is an additional alternative medicine for achieving lighter levels of sedation in suitable patients. As dexmedetomidine has been in use in several countries as a sedative agent, its risks are well known and are considered to be manageable. The European Medicines Agency therefore decided that Dexdor's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dexdor?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dexdor have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dexdor is continuously monitored. Side effects reported with Dexdor are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dexdor

Dexdor received a marketing authorisation valid throughout the EU on 16 September 2011.

Dexdor : EPAR - Medicine overview

Reference Number: EMA/648646/2011

English (EN) (91.24 KB - PDF)

**First published:** 04/10/2011

**Last updated:** 01/10/2018

[View](/en/documents/overview/dexdor-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-93)

български (BG) (110.7 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/bg/documents/overview/dexdor-epar-medicine-overview_bg.pdf)

español (ES) (83.91 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/es/documents/overview/dexdor-epar-medicine-overview_es.pdf)

čeština (CS) (107.78 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/cs/documents/overview/dexdor-epar-medicine-overview_cs.pdf)

dansk (DA) (82.11 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/da/documents/overview/dexdor-epar-medicine-overview_da.pdf)

Deutsch (DE) (84.46 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/de/documents/overview/dexdor-epar-medicine-overview_de.pdf)

eesti keel (ET) (82.26 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/et/documents/overview/dexdor-epar-medicine-overview_et.pdf)

ελληνικά (EL) (118.42 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/el/documents/overview/dexdor-epar-medicine-overview_el.pdf)

français (FR) (84.88 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/fr/documents/overview/dexdor-epar-medicine-overview_fr.pdf)

hrvatski (HR) (104.65 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/hr/documents/overview/dexdor-epar-medicine-overview_hr.pdf)

italiano (IT) (82.87 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/it/documents/overview/dexdor-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (115 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/lv/documents/overview/dexdor-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (109.14 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/lt/documents/overview/dexdor-epar-medicine-overview_lt.pdf)

magyar (HU) (103.31 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/hu/documents/overview/dexdor-epar-medicine-overview_hu.pdf)

Malti (MT) (109.84 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/mt/documents/overview/dexdor-epar-medicine-overview_mt.pdf)

Nederlands (NL) (82.78 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/nl/documents/overview/dexdor-epar-medicine-overview_nl.pdf)

polski (PL) (109.38 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/pl/documents/overview/dexdor-epar-medicine-overview_pl.pdf)

português (PT) (83.54 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/pt/documents/overview/dexdor-epar-medicine-overview_pt.pdf)

română (RO) (114.12 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/ro/documents/overview/dexdor-epar-medicine-overview_ro.pdf)

slovenčina (SK) (108.58 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/sk/documents/overview/dexdor-epar-medicine-overview_sk.pdf)

slovenščina (SL) (103.36 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/sl/documents/overview/dexdor-epar-medicine-overview_sl.pdf)

Suomi (FI) (82.33 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/fi/documents/overview/dexdor-epar-medicine-overview_fi.pdf)

svenska (SV) (82.93 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

01/10/2018

[View](/sv/documents/overview/dexdor-epar-medicine-overview_sv.pdf)

Dexdor : EPAR - Risk Management Plan

English (EN) (11.07 MB - PDF)

**First published:** 20/06/2023

**Last updated:** 11/06/2025

[View](/en/documents/rmp/dexdor-epar-risk-management-plan_en.pdf)

## Product information

Dexdor : EPAR - Product Information

English (EN) (220.53 KB - PDF)

**First published:** 04/10/2011

**Last updated:** 14/07/2022

[View](/en/documents/product-information/dexdor-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-705)

български (BG) (253.4 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/bg/documents/product-information/dexdor-epar-product-information_bg.pdf)

español (ES) (228.17 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/es/documents/product-information/dexdor-epar-product-information_es.pdf)

čeština (CS) (222.27 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/cs/documents/product-information/dexdor-epar-product-information_cs.pdf)

dansk (DA) (233.12 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/da/documents/product-information/dexdor-epar-product-information_da.pdf)

Deutsch (DE) (234.04 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/de/documents/product-information/dexdor-epar-product-information_de.pdf)

eesti keel (ET) (216.52 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/et/documents/product-information/dexdor-epar-product-information_et.pdf)

ελληνικά (EL) (298.25 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/el/documents/product-information/dexdor-epar-product-information_el.pdf)

français (FR) (235.17 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/fr/documents/product-information/dexdor-epar-product-information_fr.pdf)

hrvatski (HR) (237.38 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/hr/documents/product-information/dexdor-epar-product-information_hr.pdf)

íslenska (IS) (237.47 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/is/documents/product-information/dexdor-epar-product-information_is.pdf)

italiano (IT) (224.1 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/it/documents/product-information/dexdor-epar-product-information_it.pdf)

latviešu valoda (LV) (238.7 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/lv/documents/product-information/dexdor-epar-product-information_lv.pdf)

lietuvių kalba (LT) (222.76 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/lt/documents/product-information/dexdor-epar-product-information_lt.pdf)

magyar (HU) (236.29 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/hu/documents/product-information/dexdor-epar-product-information_hu.pdf)

Malti (MT) (266.84 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/mt/documents/product-information/dexdor-epar-product-information_mt.pdf)

Nederlands (NL) (229.46 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/nl/documents/product-information/dexdor-epar-product-information_nl.pdf)

norsk (NO) (219.78 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/no/documents/product-information/dexdor-epar-product-information_no.pdf)

polski (PL) (237.15 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/pl/documents/product-information/dexdor-epar-product-information_pl.pdf)

português (PT) (224.19 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/pt/documents/product-information/dexdor-epar-product-information_pt.pdf)

română (RO) (238.5 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/ro/documents/product-information/dexdor-epar-product-information_ro.pdf)

slovenčina (SK) (243.19 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/sk/documents/product-information/dexdor-epar-product-information_sk.pdf)

slovenščina (SL) (230.52 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/sl/documents/product-information/dexdor-epar-product-information_sl.pdf)

Suomi (FI) (221.96 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/fi/documents/product-information/dexdor-epar-product-information_fi.pdf)

svenska (SV) (225.9 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

14/07/2022

[View](/sv/documents/product-information/dexdor-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0035 08/07/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dexdor : EPAR - All Authorised presentations

English (EN) (32.81 KB - PDF)

**First published:** 04/10/2011

**Last updated:** 09/06/2016

[View](/en/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-490)

български (BG) (37.11 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/bg/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.87 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/es/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.29 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/cs/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (33.97 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/da/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (34.98 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/de/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (31.03 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/et/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.71 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/el/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_el.pdf)

français (FR) (32.02 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/fr/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (32.84 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/hr/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (33.63 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/is/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_is.pdf)

italiano (IT) (32.16 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/it/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.25 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/lv/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.14 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/lt/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.46 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/hu/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.37 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/mt/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (32.7 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/nl/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.39 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/no/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.86 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/pl/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_pl.pdf)

português (PT) (33.06 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/pt/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.93 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/ro/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.55 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/sk/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.67 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/sl/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (31.85 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/fi/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.96 KB - PDF)

**First published:**

04/10/2011

**Last updated:**

09/06/2016

[View](/sv/documents/all-authorised-presentations/dexdor-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dexdor Active substance Dexmedetomidine hydrochloride International non-proprietary name (INN) or common name dexmedetomidine Therapeutic area (MeSH) Conscious Sedation Anatomical therapeutic chemical (ATC) code N05CM18

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

## Authorisation details

EMA product number EMEA/H/C/002268 Marketing authorisation holder

Orion Corporation

Orionintie 1

Marketing authorisation issued 15/09/2011 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dexdor : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.92 KB - PDF)

**First published:** 11/06/2025

[View](/en/documents/procedural-steps-after/dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dexdor : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (212.75 KB - PDF)

**First published:** 08/05/2012

**Last updated:** 11/06/2025

[View](/en/documents/procedural-steps-after/dexdor-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Dexdor-H-C-PSUSA-00000998-202103 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/774698/2021

English (EN) (124.8 KB - PDF)

**First published:** 05/01/2022

[View](/en/documents/scientific-conclusion/dexdor-h-c-psusa-00000998-202103-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dexdor-H-C-PSUSA-00000998-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/689875/2019

English (EN) (157.6 KB - PDF)

**First published:** 03/04/2020

[View](/en/documents/scientific-conclusion/dexdor-h-c-psusa-00000998-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dexdor-H-C-2268-P46-015 : EPAR - Assessment Report

Adopted

Reference Number: EMA/547340/2019

English (EN) (580.71 KB - PDF)

**First published:** 25/11/2019

[View](/en/documents/variation-report/dexdor-h-c-2268-p46-015-epar-assessment-report_en.pdf)

Dexdor-H-C-PSUSA-00000998-201803 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/532488/2019

English (EN) (58.67 KB - PDF)

**First published:** 08/10/2019

[View](/en/documents/scientific-conclusion/dexdor-h-c-psusa-00000998-201803-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dexdor-H-C-2268-II-0026 : EPAR - Assessment Report - Variation

Reference Number: EMA/CHMP/391935/2018

English (EN) (4.54 MB - PDF)

**First published:** 01/10/2018

[View](/en/documents/variation-report/dexdor-h-c-2268-ii-0026-epar-assessment-report-variation_en.pdf)

Dexdor-H-C-PSUSA-00000998-201703 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/11066/2018

English (EN) (66.45 KB - PDF)

**First published:** 10/01/2018

**Last updated:** 10/01/2018

[View](/en/documents/scientific-conclusion/dexdor-h-c-psusa-00000998-201703-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Dexdor-H-C-2268-II-0003 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/145296/2013

English (EN) (725.71 KB - PDF)

**First published:** 18/03/2013

**Last updated:** 18/03/2013

[View](/en/documents/variation-report/dexdor-h-c-2268-ii-0003-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Dexdor : EPAR - Public assessment report

Adopted

Reference Number: EMA/789509/2011

English (EN) (1.06 MB - PDF)

**First published:** 04/10/2011

**Last updated:** 04/10/2011

[View](/en/documents/assessment-report/dexdor-epar-public-assessment-report_en.pdf)

#### News on Dexdor

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-june-2018) 29/06/2018

#### More information on Dexdor

- [Dexdor - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/dexdor)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/06/2025

## Share this page

[Back to top](#main-content)